Global Scans · Genetics · Weekly Summary

• [New] Gene editing is expected to gain fresh momentum in 2026, particularly for children with rare genetic diseases. tovima.com
• [New] A Gene, Cell & RNA Therapy Report indicated that oncology and rare diseases remain the top areas of development, which is a continuing trend, whilst advanced therapies are projected to grow at a compound annual growth rate of 18% through 2033. NES Fircroft
• [New] While Novo's secondary patents on formulations and methods extend protection into 2033 in some regions, core patent expirations will inevitably accelerate generic competition. / China Pharmaphorum
• [New] 2028 will be the first year when a negotiated drug becomes ineligible for negotiated prices for the first time because generic competition, as Januvia and Janumet are expected to have generic competition launch in mid-2026. PubMed Central (PMC)
• [New] Two years prior to the implementation of negotiated prices, CMS will begin negotiation on the top eligible drugs based on age and generic / biosimilar availability by gross spend, although negotiation for 2026 will begin in 2023 under a timeline provided by CMS. PubMed Central (PMC)
• [New] In 2026, most primary care providers at Somerville, Mass.-based Mass General Brigham will no longer be in network with MA plans from UnitedHealthcare or BCBS Massachusetts. Becker's Hospital Review | Healthcare News & A
• [New] Companies worldwide are utilizing various kinds of generative artificial intelligence applications, from large language models that can communicate in natural language to bio-design tools that can generate and predict protein-folding and new substances at the molecular level. healthcarereimagined
• [New] In 2026, quantum computing could unlock the next generation of technological advancements, and companies that invest in it now will have a significant advantage. Metana
• [New] Maternity Insurance, canton of Geneva: In 2026, the rate for both parties will slightly decrease from 0.032% to 0.029%. EY
• [New] As we move past the novelty phase of generative AI, 2026 will mark a shift toward the utility of agentic AI, and with it a growing appreciation for custom-made AI security tools tailored for an organization's specific needs. Tenable
• [New] As Generative AI matures, 2026 will mark an important stage in consumer adoption and use of large language models, with implications for online behaviour and content ecosystems. London Business School
• [New] According to Google Cloud's 2026 Cybersecurity Forecast, the most immediate risk comes from multimodal generative tools capable of manipulating voice, text, and video at the same time. Richard van Hooijdonk Blog
• [New] From hyper-realistic phishing powered by multimodal generative tools to shadow AI agents, 2026 will expose companies to greater risks than ever before. Richard van Hooijdonk Blog
• [New] Generative AI will have a nearly ubiquitous presence in 2026. Richard van Hooijdonk Blog
• [New] While investments in AI may become more cautious and results-oriented in 2026, we are still likely to see a distinct push toward generative AI and autonomous agentic systems; one that will be reflected in capital investment. Richard van Hooijdonk Blog
• [New] In a best-case scenario, agentic AI could generate close to 30% of all enterprise application software revenue by 2035, totalling more than US$450bn. Richard van Hooijdonk Blog
• [New] Successful companies will rethink their data and evidence generation strategies to drive success in RWE efforts, including collaboration with other firms and participation in data marketplaces. pharmexec
• [New] In 2026, leading brands will spend more on AI-led innovation, often at the expense of traditional sales, general, and administrative expenses. pharmexec
• [New] 86% of advertisers are already using or plan to use generative AI for video ad production, and projected adoption suggests Gen AI-created video ads will represent ~40% of all video ads by 2026. The Gradient Group
• [New] The most generational 2026 AI trends are expected to transform the way companies operate, innovating, collaborating, and engaging with their customers. Rain Infotech
• [New] Three other important areas that will shape decisions in health system pharmacy in 2026 are the continued growth of cell and gene therapy, the ongoing workforce challenges, and the need to embrace artificial intelligence - assisted solutions. Pharmacy Times
• [New] The first CCS project began operations in 2025, and additional projects with partners like Linde, Nucor, and New Generation Gas Gathering will start up in 2026. JPT
• [New] 2025 will bring AI innovations across pharmaceutical drug discovery, genetics, and biotech. AI Health Uncut

Last updated: 04 January 2026